博客

血友病

Altuviiio: A Once-Weekly Treatment for Hemophilia A

Patient in an office discussing Altuviiio with a healthcare professional

FDA-approved in February 2023, Sanofi’s Altuviiio is a long-acting antihemophilic factor (recombinant) used to treat 血友病A in children and adults. Learn about its mechanism of action, dosage, side effects, cost, and more. 

Do You Qualify for $0 Copay?

Talk to a Specialist to Find Out
(877) 778-0318

Important Warnings and Precautions

过敏反应

This medication may cause allergic reactions, which can be fatal. Seek emergency medical care if you experience:

  • 气促
  • 哮鸣
  • 麻疹
  • 胸闷
  • 低血压
  • 瘙痒

Inhibitor Production

In some cases, your body can make proteins called “inhibitors”, which can stop this medication from working as intended. 

如果您的免疫系统产生抑制物,您需要特殊治疗来控制出血。请咨询您的医疗保健提供者,了解更多关于抑制物以及测量抑制物水平的检测方法的信息。 

Before Taking Altuviiio

Before you receive your first dose, inform your provider if you:

  • Have or had any medical issues.
  • Are allergic to this product, any product component, or any other medications.
  • Are pregnant or planning to get pregnant. It is unknown if this medication harms your unborn baby. 
  • Are breastfeeding. It is unknown if this medication is present in breast milk, and if it can harm the baby. 

Altuviiio Introduction and Uses

Altuviiio injection is a brand-name prescription product. It contains the active ingredient “recombinant clotting factor VIII”, also called the recombinant antihemophilic factor. Altuviiio belongs to a class of medications called antihemophilic factors. 

A healthcare provider may prescribe this medication for children and adults with hemophilia A to: 

  • 控制和预防出血事件
  • 预防手术期间出血
  • 减少出血频率

In people with hemophilia A, blood doesn’t clot properly because they have a deficiency of coagulation factor VIII. Factor VIII deficiency increases the risk of unexplained bleeding or, in severe cases, potentially fatal internal bleeding. 

This medication shouldn’t be used to treat another similar bleeding disorder called 血管性血友病.

获得经济援助

开始

Altuviiio Mechanism of Action

Blood sample tube and paper order request for factor VIII test analysis

Three components in Altuviiio work together to stop the bleeding. They are:

  • Fc Fusion, which helps Factor VIII recirculate in the blood. 
  • XTEN Technology, which helps prevent the early breakdown of Factor VIII. 
  • vWF Fragments, which help Factor VIII stay longer in the blood.

Altuviiio’s half-life is three to four times greater than other Factor VIII products. This means the medication remains in the body for longer, enabling a once-weekly dosing schedule. 

Altuviio Dosage

This medication is supplied as a sterile white-to-off-white powder for reconstitution prior to intravenous (IV) injection in single-dose vials. 

美国具有以下优势: 

  • 250国际单位
  • 500国际单位
  • 750国际单位
  • 1,000 国际单位
  • 2,000 国际单位
  • 3,000 国际单位
  • 4,000 国际单位

Before administering this medication, your healthcare provider will use a specific formula to determine the dose. Then, they will prepare the liquid for injection according to the instructions on the package. 

治疗剂量和持续时间取决于:

  • 体重
  • Ⅷ因子缺乏的严重程度
  • 期望的Ⅷ因子水平

Dosing for Routine Prophylaxis (Prevention)

For children and adults: 50 IU/kg of Altuviiio administered once weekly. 

Dosing for Control of Bleeding Episodes

  • Minor and moderate bleeding: Single dose of 50 IU/kg. 
  • Major bleeding: Single dose of 50 IU/kg. 

Dosing for Preventing Bleeding During Surgery

  • Minor surgery: Single dose of 50 IU/kg. An additional dose of 30 or 50 IU/kg may be considered 2 to 3 days after surgery (post-operative dose).
  • Major surgery: Single dose of 50 IU/kg. If needed, a healthcare provider may administer additional doses of 30 or 50 IU/kg every 2 to 3 days.

与专家交谈

关于共付额援助
(877) 778-0318

Altuviiio Side Effects

Headache and joint pain are the most common side effects. Inform your healthcare provider if other side effects occur. 

Altuviiio Proper Use

Your healthcare provider will teach you or your caregiver how to mix and administer Altuviiio when used for the first time. 

Important Things To Know Before Injecting Altuviiio

  • Read all instructions carefully. If you have any questions, talk to your healthcare provider. 
  • Before injecting, you should mix Altuviiio powder with liquid that comes in a prefilled syringe. 
  • The solution is administered intravenously. 
  • Don’t use Altuviiio if it has been damaged, the solution is cloudy, or if the syringe cap is not securely attached. 

Altuviiio Storage and Handling 

Before Preparing the Solution

  • Store in the original package.
  • 保持储存温度在 2°C 至 8°C (36°F 至 46°F) 之间。避免冻结。
  • You may store this medication at room temperature (maximum temperature 30°C or 86°F) for up to 6 months in a row.
  • After you remove the product from the refrigerator, allow the vial and prefilled syringe to come to room temperature before injecting. 
  • Never put the vial or prefilled syringe in hot water. 
  • 一旦达到室温,就避免将产品放回冰箱。
  • Keep the product away from direct sunlight. 

After Preparing the Solution

  • Avoid direct sun exposure. 
  • 混合后,请在 3 小时内使用该溶液。 
  • Don’t refrigerate after preparing the solution. 

Altuviiio Cost

Cost can vary depending on your insurance plan, location, and pharmacy. Contact your insurance provider to determine whether your plan covers this medication and whether prior authorization is required.

Sanofi Corporation, the manufacturer of Altuviiio, offers financial assistance through its HemAssist™ program. You can also enroll in the copay program and the free-trial program. 

点击这里 to talk about your options with one of our financial assistance specialists. 

立即获得共付额援助

联系我们

Altuviiio vs. Hemlibra

Both medicines are used to help prevent bleeding in people with hemophilia A. But these medicines differ in their mechanism of action and route of administration. According to a 2024 study, Altuviiio may be superior to Hemlibra in preventing bleeding in certain patients with hemophilia A [1]. Your healthcare provider will help determine the most appropriate medication for your condition.

参考:

  1. Álvarez Román, M.T., Kragh, N., Guyot, P. et al. Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors. Adv Ther 42, 442–455 (2025). https://doi.org/10.1007/s12325-024-03031-4
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
Portrait of Christine L., a healthcare professional, smiling confidently.
医学审核人 Christine Leduc 博士,药学博士

Christine Leduc 博士,药学博士,在加州尔湾市出生长大。她就读于中西部大学,并以优异成绩毕业。她工作中最有成就感的部分是建议改变生活方式,教育患者了解药物的药理作用,以及指导未来的药剂师。她的专业领域是客户服务和专科药物知识。她曾在服务行业工作,积累了理解患者需求所需的客户服务技能。Leduc 博士目前正在指导马歇尔·B·凯彻姆大学、堪萨斯大学和中西部大学的学生。闲暇时,她喜欢旅行、烘焙和园艺。 参见作者简介

联系我们

If you are interested in speaking to a specialist or wish to explore financial assistance opportunities, use the contact form below to get in touch with us.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知